Compare Abeona Therapeutics Inc (ABEO) vs Autozone Inc (AZO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Autozone Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Autozone Inc trades at $3,080.43 (market cap $50.20B). The key difference: Autozone Inc is far larger — about 134.5× Abeona Therapeutics Inc's market cap, and Autozone Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | AZO | |
|---|---|---|
Market Cap | $373.32M | $50.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $4.35K |
52-Week Low | $4.17 | $2.94K |
Enterprise Value | $228.22M | $62.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AutoZone (AZO) trades at $3,074.86, down 2.67% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though profit margins have declined from 14.94% in 2022 to 13.19% in 2025. Recent Q1 2026 earnings beat expectations at $38.07 EPS versus $36.22 expected, while the board authorized an additional $1.5B stock repurchase in June 2026.
AZO presents a mixed outlook with 72.7% analyst buy ratings and $3,740 consensus target suggesting 21.6% upside, but faces technical headwinds and margin compression risks. Investment appeal hinges on international expansion execution and commercial segment growth offsetting domestic softness noted in recent earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
